Sarwer, David B.
Dilks, Rebecca J.
Spitzer, Jacqueline C.
Berkowitz, Robert I.
Wadden, Thomas A.
Moore, Renee H.
Chittams, Jesse L.
Brandt, Mary L.
Chen, Mike K.
Courcoulas, Anita P.
Harmon, Carroll M.
Helmrath, Michael A.
Michalsky, Marc P.
Xanthakos, Stavra A.
Zeller, Meg H.
Jenkins, Todd M.
Inge, Thomas H.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK080738, K24-DK065018, U01DK072493)
Pennsylvania Department of Health (SAP4100033130)
National Center for Research Resources (UL1RR024134)
National Center for Advancing Translational Sciences (UL1TR000003)
Article History
First Online: 17 June 2017
Compliance with Ethical Standards
:
: Work on this paper was supported, in part, by the National Institute of Diabetes and Digestive and Kidney Diseases (Grants R01-DK080738 to Dr. Sarwer and K24-DK065018 to Dr. Wadden and U01DK072493 to Dr. Inge), the Pennsylvania Department of Health SAP4100033130 to Dr. Berkowitz, and the Clinical & Translational Research Center at the University of Pennsylvania and The Children’s Hospital of Philadelphia supported by grants UL1RR024134 (NCRR) and UL1TR000003 (NCATS).
: Author A reports received consulting fees from the following: BARONova, Ethicon Endosurgery, Medtronic, and Novo Nordisk. Author B reports receiving fees for serving on the Advisory Board for Orexigen Pharmaceutical and Nutrisystem. He reports receiving grants and advisory board fees from Novo Nordisk and Weight Watchers. He also reports receiving grant funding from Eisai Pharmaceutical and royalties from Guilford Press for two edited books. Author C reports consulting fees from Sanofi Corporation and grant funding from Ethicon Endosurgery.